Evidence map›Paper›PMID 36699056›Full record

ReviewFrontiers in pharmacology2022

Engineered elastin-like polypeptides: An efficient platform for enhanced cancer treatment.

Aiguo Jiang, Xinqiang Guan, Lianping He, Xingang Guan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aiguo JiangDepartment of Respiratory Medicine, Taizhou University Affiliated Wenling Hospital, Taizhou University, Taizhou, China.
Xinqiang GuanDepartment of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Lianping HeDepartment of Basic Medicine, School of Medicine, Taizhou University, Taizhou, China.
Xingang GuanDepartment of Respiratory Medicine, Taizhou University Affiliated Wenling Hospital, Taizhou University, Taizhou, China.
Lanzhou University Second Hospital · CNTaizhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug delivery systems (DDSs) have recently gained widespread attention for improving drug loading and delivery efficiency in treating many cancers. Elastin-like polypeptides (ELPs) are synthetic peptides derived from a precursor of elastin (tropoelastin), reserving similar structural and physicochemical properties. ELPs have gained a variety of applications in tissue engineering and cancer therapy due to their excellent biocompatibility, complete degradability, temperature-responsive property, controllable sequence and length, and precisely tuned structure and function. ELPs-based drug delivery systems can improve the pharmacokinetics and biodistribution of therapeutic reagents, leading to enhanced antitumor efficacy. In this review, we summarize the recent application of ELPs in cancer treatment, focusing on the delivery of functional peptides, therapeutic proteins, small molecule drugs, and photosensitizers.

Indexed as

cancer therapydrug deliveryelastin-like polypeptideinverse transition cyclingnanoparticle

Identifiers

PMID36699056
PMCPMC9868590
OpenAlexW4313890486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.